MedTrace Logo

CTCs in Cervix Cancer

NCT04064515 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 4

Last updated 2022-08-05

No results posted yet for this study

Summary

This study is a validation study to confirm the ability of Telomescan OBP-401 to identify CTCs in patients with HPV 16 / 18 associated cervical cancer. CTCs identified will be tested for the presence of the HPV 16 / 18 E6 protein, confirming a cervical cancer origin.

Conditions

Interventions

DIAGNOSTIC_TEST

Blood Assayed for CTCs

All study participants will have 15 mL of blood drawn for the purpose of the study.

Sponsors & Collaborators

Principal Investigators

  • Leslie Boyd, MD · NYU Langone Health

Eligibility

Min Age
18 Years
Max Age
100 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-03-02
Primary Completion
2020-04-23
Completion
2020-04-23

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04064515 on ClinicalTrials.gov